EGFR and cancer: We demonstrated in this study that the multivalent Rha‐7D12 conjugate D5, which was resistant to PRSS degradation, had significantly enhanced Fc effector functions, and had the potential to target acquired resistance mutations of EGFR, is a new modality that has the potential for clinical transformation in cancer immunotherapy.